

December 1, 2025

Price (close on November 28, 2025)
\$3.57

Rating
Buy-Extended

12- Month Target Price
\$9.00

Andrew White, CFA
Research@EmergingGrowth.com

About the Company

SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers via a franchise model in Japan, Vietnam, Thailand, and Singapore. Revenue is sourced from five segments: Franchising, Procurement, Management Services, Rental, and Other. The Company was founded in 2000.

52-Week Range	\$2.62 - \$7.99
Shares Outstanding	103 mil
Insider/Institutional	87%/0%
Public Float	\$33 mil
Market Capitalization	\$340 mil
Total Debt	\$21 mil
Debt / Equity	8%
ROE (TTM)	21%
Book Value / Share	\$2.42
Daily Volume (90-day)	51,500
Fwd. Div. & Yield	--

Keep Looking Through Valley to Expansion:

Long-term accomplished founder and management have transformed SBC from a solo clinic in 2000 to a global cosmetic treatment center franchiser and cash generation machine with little debt. However, revenue growth has declined in recent quarters yoy (which is expected to persist into early-2026), reflecting increased market competition pressure. However, revenue stabilized sequentially in Q3:25. Looking through the valley sees the Company growing again in early-2026 with prospects for global M&A in addition to opportunistic Japanese M&A. SBC remains heavily undervalued traditionally and via a DCF analysis (especially net of ample Net Cash). We are bullish and **reiterate a Buy-Extended rating with a \$9.00 price target.**

FYE Dec Revenue (\$ mil.)	FY 2024A	FY 2025E		FY 2026E	
	ACTUAL	CURRENT	FORMER	CURRENT	FORMER
Q1 Mar	\$54.8A	\$47.3A	\$47.3A	\$43.4E	\$43.4E
Q2 Jun	\$53.1A	\$43.4A	\$43.4A	\$48.8E	\$48.8E
Q3 Sep	\$53.1A	\$43.4A	\$43.4E	\$48.8E	\$48.8E
Q4 Dec	\$44.4A	\$43.4E	\$43.4E	\$48.8E	\$48.8E
Year*	\$205.4A	\$177.4E	\$177.4E	\$189.7E	\$189.7E
Change	6%	(14)%	(14)%	7%	7%

FYE Dec EPS (\$)	FY 2024A	FY 2025E		FY 2026E	
	ACTUAL	CURRENT	FORMER	CURRENT	FORMER
Q1 Mar	\$0.20A	\$0.21A	\$0.21A	\$0.10E	\$0.09E
Q2 Jun	\$0.20A	\$0.02A	\$0.02A	\$0.13E	\$0.12E
Q3 Sep	\$0.03A	\$0.13A	\$0.10E	\$0.13E	\$0.12E
Q4 Dec	\$0.06A	\$0.10E	\$0.10E	\$0.13E	\$0.12E
Year*	\$0.48A	\$0.46E	\$0.42E	\$0.49E	\$0.46E
P/E Ratio	6.9	7.2	9.6	6.8	8.8



Q3:25 Financial Performance

- Revenue remains under yoy pressure, but revenue and sequential quarterly operating profit stabilized. Cash remains strong.
- Dominant franchise position in the local Japanese industry with underlying volume growth, though near-term sales pricing pressure
- 25-year track record with founder management founder and M&A (e.g., AHH in Singapore)
- Heavily discounted shares with increasing steps by management to improve liquidity in share trading

Key Risks

- Potentially longer-than-expected revenue rebound expected on increased competition, though importantly not being seen in volumes.
- Japanese market and franchisee concentration presents diversifiable risks – less of an issue with future global M&A
- Limited international experience in SE Asia and U.S. markets that are targets for global M&A (judicious in approach then)
- Relatively small share free float hampers liquidity, though steps are being taken to change this reality

Investment Thesis

SBC underwent financial recapitalization in Q3:24, during which the holding company Pono Capital Two, Inc. (“Pono”) merged the business lines of prior SBC businesses and renamed itself SBC Medical Group Holdings, Inc. Collectively, the Company is now the largest player in Japanese cosmetic treatment with an estimated 25% market share in the highly-fragmented industry in which the Company currently generates 99% of revenue.

The Company operates reasonable prices/a high turnover model (e.g., Shonan Beauty dermatology, Gorilla Clinic) as well as higher-growth/higher-margin dermatological aesthetics (e.g., JUN Clinic, NEO Skin Clinic), including an increasing focus on male customers. SBC also has expanded internationally with management recruitment, acquisition of AHH in Singapore, and a partnership with BLEZ ASIA in Thailand. An additional acquisition of Waqoo in Japan is pending a successful tender offer, which will then focus on R&D to provide new services to SBC’s clinics.

SBC clinics have continued to grow organically and via acquisitions (i.e., +34 total SBC clinics or +15% in last 12 months to reach a total of 258 clinics). The goal is to grow from 258 clinics currently to 1,000 in ten years, implying a 15% long-term CAGR in clinics. The Company now reports 6.5 million visits annually (which is unmatched in Japan) and a 72% repeat rate. Average revenue per visit is also trending up to \$298 in Q3:25 from \$275 in Q1:25, despite fierce competition.

Since mid-2024 (around the time of Q3:24 recapitalization), SBC shares have declined ~80%, reflecting expectations of and reality of near-term revenue slowdown in later 2024 through early 2026E due to increased local market competition. Indeed, a Q2:25 change in franchise fee pricing structure has reduced quarterly revenue expected over the following three quarters (including Q4:25E-Q1:26E) from a ~\$55 million run rate for most of 2024 to a ~\$45 million run rate currently. It is expected that revenue generation will remain at the ~\$45 million level until Q1:26 after which it should return to its historical +10% to +15% CAGR range. Importantly, operating-profit is being kept in-line on a sequential quarterly basis, as evidenced in Q3:25.

With growing underlying procedure volume, 70%-75% gross margins, and operating expense control (reflecting the franchise model), SBC is a cash-generation machine. As of the end of Q3:25, the Company carried \$127 million in cash on the balance sheet, an additional \$83 million in accounts receivable, and \$15 million in pre-paid expenses. Net of limited \$21 million long-term commercial bank loans (i.e., low-APR borrowing in Japan), current assets are approximately 65% of SBC’s total assets or ~55% of its current fully-diluted \$340 million market capitalization (~40% in Net Cash alone). In effect then, net-of-cash price of SBC shares is \$1 to \$2 per share, not the listed \$3.31 per share price as of November 21, 2025.

Accordingly, SBC is heavily discounted with best yet to come on both domestic Japanese and global expansion, post-2025 treatment pricing change. Moreover, to improve trading liquidity, SBC has also taken several steps: became a Russell 3000 company (June 2025) and executed a share buyback earlier this year. Furthermore, the Company is contemplating the potential creation of a dividend program, partial liquidation of its founder’s share ownership, and perhaps an additional share issuance to support global M&A activity. **We are bullish and reiterate a Buy-Extended rating with a \$9.00 price target.**

Q3:25 Financial Performance

SBC’s revenue declined (18)% yoy in Q3:25 at \$43.4 million versus \$53.1 million in Q3:24, yet sequentially stabilized versus \$43.4 million in Q2:25. This result reflected the impact of franchising fee reductions, reduced orders for medical materials, and the Company’s withdrawal from staffing business, partially offset by rising prices in Rental Services and consolidation of the AHH acquisition. Underlying volumes increased as 34 more locations were added yoy (i.e., franchise locations were 258 as of September 30, 2025) and customer number increased +14% yoy (i.e., to 6.5 million customers in the twelve months ended September 30, 2025 with a repeat rate of 72%). Management estimates that total revenue will be negatively impacted for the next two quarters through Q1:26, as the effect of the revised fee structure for clinic service is fully absorbed.

Gross profit in Q3:25 was \$30.6 million compared to \$43.2 million in Q3:24 reflecting the decline in higher-margin Franchising and Management Services revenue. Sequentially, gross profit stabilized versus \$30.0 million in Q2:25. Operating profit in Q3:25 rose to \$15.9 million compared to \$13.8 million in Q3:24 due to the absence of stock-based compensation costs related to the prior year’s listing process. Sequentially, operating profit also increased from \$14.6 million in Q2:25. SBC’s Net Income from Continuing Operations in Q3:25 rose strongly to \$12.8 million versus \$2.8 million in Q3:24 on lower income tax expense. Sequentially, Net Income from Continuing Operations also rose from \$2.5 million in Q2:25. Adjusted EBITDA, a non-GAAP measure, was \$16.8 million in Q3:25 versus \$14.8 million in Q3:24 and \$15.5 million in Q2:25. EPS rose strongly to \$0.13/share from \$0.03 in Q3:24 and \$0.02 sequentially in Q2:25.

Cash remained plentiful, though at a lower-than-expected \$127 million level, on a Receivables increase reflecting changed customer payment terms partially offset by larger income tax payable. Debt load remains low at 8% Debt/Equity.

EPS Guidance, Estimates, and Valuation

SBC management estimates that while revenue will continue to be negatively impacted for the next two quarters by the effect of recent price changes, operating profit for full year 2025 should be approximately equal to that of 2024. This expectation implies an operating profit stabilization in H2:25 versus Q2:25, which is what we saw in Q3:25. +10% to +15% CAGR revenue growth thereafter is expected to return reflecting both domestic return to organic growth as well as select M&A activity in Japan, Southeast Asia, and the United States. Importantly, we step-down revenue growth by (1)%/year from 2028-2034. Gross margin is expected to stabilize at ~70% while Operating margin is expected to slowly recover to ~40%.

We traditionally value companies using a blend of peer group relative valuation multiples and a Discounted Cash Flow (DCF) model. However, SBC is a unique Company in the niche Japanese/global cosmetic treatment industry. Most of its industry is fragmented, and there are few publicly-traded true comparables. The closest peer in the United States is AIRS, which has a higher Price/Sales ratio despite being unprofitable/low-growth with a higher debt-load/stock volatility.

So, we currently downplay our relative valuation analysis. That said, even a cursory glance at SBC’s Price/Earnings, Price/Sales, and PEG ratios make it clear that SBC is undervalued (especially net of Cash or Current Assets). Moreover, the Company’s considerable Net Cash on the balance sheet (~30% of market value as of 9/30/2025 or ~55% of Net Current Assets) calls for a Discounted Cash Flow (“DCF”) analysis. Exhibit 1 below summarizes our peer group multiples. Historical and proforma forecast financial statements as well as a DCF model are included on pages six through ten of this report.

Exhibit 1: SBC Medical Group Holdings, Inc. Peer Group Multiples and Price Target

SBC Medical Group Holdings, Inc.
 Peer Group Valuations

Company Name	Ticker	Price (11/21/24)	Shares (MM)	Market Cap (\$millions)	Trailing Price/Sales	Forward P/Sales	Trailing P/E	Forward P/E	Forward PEG
Airsulpt Tech	AIRS	\$3.66	62.4	\$229	2.4	1.5	NM	NM	NM
Industry Averages (ex: negatives)				\$229	2.4	1.5	NM	NM	NM
SBC Medical Group Holdings, Inc.	SBC	\$3.31	102.6	\$340	1.9	1.8	7.8	7.3	0.9
SBC (Adj. for Net Cash on Q4:25E Balance Sheet)	SBC	\$2.17	102.6	\$340	1.2	1.2	5.1	4.8	0.6
SBC (Adj. for Current Assets on Q4:25E Balance Sheet)	SBC	\$0.99	102.6	\$340	0.6	0.6	2.4	2.2	0.3
Discounted Cash Flow Estimate		\$8.88							

Source: *Emerging Growth Research and SBC Medical Group Holdings, Inc.*

Our DCF model uses financial statement estimates for 2025 and 2026 and projections for years thereafter. We focus on Free Cash Flow, which we expect to resume +12.5% CAGR expansion in later 2026 (mid-point of +10% to +15% range), with rate of growth declining (1)% each year to a terminal 3% growth rate achieved ten years from now in 2035. Operating margin is expected to remain at an average 40% over the period covered. We believe these estimates are conservative.

We discount estimated annual free cash flows by 11.1% WACC, inclusive of risk premiums for the risk-free-rate, equity market, trading liquidity, and small-cap risk. Our DCF model produces a \$8.88/share present value of equity (inclusive of cash and warrants), which we round up to \$9.00. Sensitivity analysis (for different terminal growth and discount rates) indicates a min/max share price-estimate range of \$7.33 - \$12.51, which adds confidence in our price target estimate.

Our price target is materially higher than the current \$3.57 price of SBC shares as of November 28, 2025. Investors significantly sold off SBC shares in 2024, but shares have stabilized in 2025 on operating earnings steadiness/re-testing of Q1:25 lows. We focus on the future. If management is able to continue stabilization of operating profit and regrow its top-line in 2026, share price upside is considerable. **We reiterate a Buy-Extended rating and a \$9.00 price target.**

Important Disclosures

Emerging Growth.com ("EG") is a publisher and distributor of branded investment research reports provided by Emerging Growth Research LLC ("EGR Report") focused on both public and private companies. This report was prepared for institutional and professional investors ONLY, and it is also known as Company Sponsored Research ("CSR"). Collectively, however ("EGR Report(s)").

Be advised that this EGR Report is being provided by Emerging Growth Research LLC (EGR) solely for informational purposes, is not the opinion of EG, should not be construed as an offer or solicitation to buy or sell securities, and should not be considered in any decision to buy or sell any security mentioned within the EGR Reports. All information contained in the EGR Report as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive, timely, or correct. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. Because EGR is compensated as detailed herein and EG receives Licensing fees from EGR, as also detailed herein, EG and EGR have a conflict of interest and strongly urge you to consult your own independent financial, investment, tax, and legal advisors prior to purchasing or selling any securities mentioned herein.

The analyst that has prepared and is responsible for the content of this report has stated that neither he/she, nor any of his/her associates both professional and personal, to the best of his/her knowledge have no personal or professional relationship with any of the companies or principals of any companies mentioned within, other than providing services that EGR may offer.

EGR is being compensated by the subject Company of this report. EGR was paid thirty-three thousand dollars and does not expect to receive an additional amount over the following 12 months. EGR may have also received additional past compensation, EGR may receive future compensation, and EG may receive compensation for additional services such as presenting on the Emerging Growth Conference or investor or public relations services, details about which can be found in the full disclosure, here: <https://EmergingGrowth.com/sbc-egr-report-disclosure/>.

It is the intent of EGR to provide continuing coverage on a quarterly basis, or otherwise for the subject Company of this report; however, EGR and EG will not notify readers of this report if coverage by EGR, for any reason is terminated.

The reader or user of this content agrees that neither EGR and / or EG nor the analysts, directors, officers, employees, representatives, independent contractors, agents or affiliates of EGR and EG shall be liable or held liable for any omissions, errors, or inaccuracies, regardless of cause, foreseeability, or the lack of timeliness of this or any of our other reports to users. This lack of liability extends to direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, losses, lost income, lost profit, or opportunity costs.

Again, all information contained herein should be independently verified by your own research and your own independent financial, investment, tax, and legal advisors prior to purchasing or selling any securities mentioned herein.

In addition to the specific disclosures mentioned herein, you are encouraged to read our general disclosure here: EmergingGrowth.com/Disclosure.

Rating Definitions

Buy, 30% or greater price appreciation in the next 12 months.

Buy-Extended, near-term EPS and/or revenue horizon is challenging with strong long-term appreciation possibility.

Buy-Emerging, initial stages with low revenue and the potential for large returns with higher risk and volatility.

Hold, perform similar to market.

Sell, 30% or more decline in the next 12 months.

© Copyright 2025 Emerging Growth Research LLC

No part of this material may be copied, photocopied, or duplicated in any form by any means or redistributed without the prior written consent of Emerging Growth Research LLC.

5-Year Chart



SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
 Quarterly Results & Estimates
 \$ in Millions

	2023 Actual	2024 Actual	2025 Estimated					2026 Estimated				
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QE Dec-25	Fiscal 2025E	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Revenues												
Franchising	\$ 42.10	\$ 61.03	\$ 15.72	\$ 10.01	\$ 9.93	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Procurement	\$ 53.19	\$ 54.81	\$ 14.33	\$ 15.76	\$ 13.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Management Services	\$ 72.28	\$ 53.11	\$ 8.73	\$ 5.14	\$ 9.46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Rental Services	\$ 7.34	\$ 16.14	\$ 5.64	\$ 6.85	\$ 6.22	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other	\$ 18.63	\$ 20.31	\$ 2.91	\$ 5.61	\$ 4.34	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Elimination of intercompany transactions	\$ -	\$ -	\$ -	\$ -	\$ -	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TOtal Revenues	\$ 193.54	\$ 205.42	\$ 47.33	\$ 43.36	\$ 43.35	\$ 43.35	\$ 177.40	\$ 43.35	\$ 48.78	\$ 48.77	\$ 48.77	\$ 189.68
YOY Revenue Growth (%)	N/A	6.1%	-13.6%	-18.3%	-18.3%	-2.4%	-13.6%	-8.4%	12.5%	12.5%	12.5%	6.9%
Cost of Revenues	\$ 56.24	\$ 49.37	\$ 9.60	\$ 13.35	\$ 12.74	\$ 12.74	\$ 48.43	\$ 13.06	\$ 13.06	\$ 13.06	\$ 13.06	\$ 52.24
Cost of Revenues/Sales (%)	29.1%	24.0%	20.3%	30.8%	29.4%	29.4%	27.3%	30.1%	26.8%	26.8%	26.8%	27.5%
Gross Profit	\$ 137.31	\$ 156.05	\$ 37.73	\$ 30.01	\$ 30.61	\$ 30.61	\$ 128.97	\$ 30.29	\$ 35.72	\$ 35.71	\$ 35.71	\$ 137.44
Gross Margin	70.9%	76.0%	79.7%	69.2%	70.6%	70.6%	72.7%	69.9%	73.2%	73.2%	73.2%	72.5%
SG&A	\$ 66.24	\$ 70.69	\$ 13.53	\$ 15.46	\$ 14.73	\$ 14.73	\$ 58.45	\$ 15.17	\$ 15.17	\$ 15.17	\$ 15.17	\$ 60.69
% of sales	34.2%	34.4%	28.6%	35.6%	34.0%	34.0%	32.9%	35.0%	31.1%	31.1%	31.1%	32.0%
Depreciation, depletion & amortization	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
% of sales	#DIV/0!	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Impairment of goodwill	\$ -	\$ 15.06	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain on disposal of assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 0.41	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of other long-lived assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total Operating Expenses	\$ 66.64	\$ 85.75	\$ 13.53	\$ 15.46	\$ 14.73	\$ 14.73	\$ 58.45	\$ 15.17	\$ 15.17	\$ 15.17	\$ 15.17	\$ 60.69
% of sales	34.4%	41.7%	28.6%	35.6%	34.0%	34.0%	32.9%	35.0%	31.1%	31.1%	31.1%	32.0%
Operating Profit	\$ 70.66	\$ 70.30	\$ 24.20	\$ 14.56	\$ 15.88	\$ 15.88	\$ 70.52	\$ 15.12	\$ 20.55	\$ 20.54	\$ 20.54	\$ 76.75
Operating Margin	36.5%	34.2%	51.1%	33.6%	36.6%	36.6%	39.8%	34.9%	42.1%	42.1%	42.1%	40.5%
Interest expense and financing charges, net	\$ (0.05)	\$ (0.03)	\$ (0.01)	\$ (0.03)	\$ (0.05)	\$ (0.05)	\$ (0.13)	\$ (0.05)	\$ (0.05)	\$ (0.05)	\$ (0.05)	\$ (0.20)
Interest expense and financing charges, net - related parties	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other income, net	\$ 3.62	\$ 4.81	\$ 7.20	\$ 0.03	\$ 0.15	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other, net - related parties	\$ (0.66)	\$ (1.63)	\$ 0.06	\$ (1.02)	\$ 2.53	\$ 1.33	\$ -	\$ 1.48	\$ 1.55	\$ 1.68	\$ 1.82	\$ 6.54
Pretax Income	\$ 73.58	\$ 73.46	\$ 31.45	\$ 13.54	\$ 18.51	\$ 17.16	\$ 80.66	\$ 16.55	\$ 22.05	\$ 22.18	\$ 22.31	\$ 83.09
Income Tax (benefit)	\$ 35.02	\$ 26.77	\$ 9.96	\$ 11.10	\$ 5.67	\$ 6.86	\$ 33.60	\$ 6.62	\$ 8.82	\$ 8.87	\$ 8.92	\$ 33.24
Effective tax rate	48%	36%	32%	82%	31%	40%	42%	40%	40%	40%	40%	40%
Income (Loss) attributable to minority interests	\$ (0.81)	\$ 0.08	\$ (0.01)	\$ (0.02)	\$ (0.01)	\$ (0.01)	\$ (0.05)	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ (0.04)
GAAP Net Income from Continuing Operations	\$ 39.37	\$ 46.61	\$ 21.50	\$ 2.46	\$ 12.84	\$ 10.30	\$ 47.11	\$ 9.94	\$ 13.24	\$ 13.31	\$ 13.40	\$ 49.89
Foreign currency adjustment	\$ 12.89	\$ 16.56	\$ (9.81)	\$ (8.62)	\$ 6.79	\$ -	\$ (11.64)	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 0.01	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Income (Loss) attributable to minority interests	\$ (0.95)	\$ 0.12	\$ (0.04)	\$ 0.18	\$ 0.01	\$ 0.05	\$ 0.21	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.20
Comprehensive income (loss)	\$ 27.42	\$ 29.94	\$ 31.35	\$ 10.90	\$ 6.04	\$ 10.25	\$ 58.54	\$ 9.89	\$ 13.19	\$ 13.26	\$ 13.35	\$ 49.69
Shares for Basic EPS (millions of shares)	94.19	96.56	103.28	103.51	102.64	102.64	103.02	102.64	102.64	102.64	102.64	102.64
Shares for Diluted EPS (millions of shares)	94.19	96.56	103.28	103.51	102.64	102.64	103.02	102.64	102.64	102.64	102.64	102.64
EPS Basic	\$ 0.42	\$ 0.48	\$ 0.21	\$ 0.02	\$ 0.13	\$ 0.10	\$ 0.46	\$ 0.10	\$ 0.13	\$ 0.13	\$ 0.13	\$ 0.49
EPS Diluted	\$ 0.42	\$ 0.48	\$ 0.21	\$ 0.02	\$ 0.13	\$ 0.10	\$ 0.46	\$ 0.10	\$ 0.13	\$ 0.13	\$ 0.13	\$ 0.49
GAAP Earnings Growth	N/A	14.3%	5.4%	-87.9%	317.0%	57.8%	-4.3%	-53.9%	442.4%	3.7%	30.0%	5.8%

N/A – Data not currently available

SBC Medical Group Holdings, Inc.
Nasdaq: SBC
Quarterly EBITDA
\$ in Millions

	2023 Actual	2024 Actual	2025 Estimated				2026 Estimated					
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QE Dec-25	Fiscal 2025E	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Net income	\$ 39.37	\$ 46.61	\$ 21.50	\$ 2.46	\$ 12.84	\$ 10.30	\$ 47.11	\$ 9.94	\$ 13.24	\$ 13.31	\$ 13.40	\$ 49.89
Interest expense	\$ -	\$ 0.03	\$ 0.01	\$ 0.03	\$ 0.05	\$ 0.05	\$ 0.13	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.20
Income tax (benefit)	\$ -	\$ 26.77	\$ 9.96	\$ 11.10	\$ 5.67	\$ 6.86	\$ 33.60	\$ 6.62	\$ 8.82	\$ 8.87	\$ 8.92	\$ 33.24
Depreciation, depletion & amortization	\$ 12.25	\$ 3.80	\$ 0.93	\$ 0.93	\$ 0.93	\$ 0.93	\$ 3.71	\$ 0.92	\$ 0.92	\$ 0.92	\$ 0.92	\$ 3.67
EBITDA	\$ 51.62	\$ 77.21	\$ 32.39	\$ 14.52	\$ 19.49	\$ 18.14	\$ 84.54	\$ 17.53	\$ 23.02	\$ 23.15	\$ 23.29	\$ 86.99
EBITDA Margin (%)	26.7%	37.6%	68.4%	33.5%	45.0%	41.9%	47.7%	40.4%	47.2%	47.5%	47.7%	45.9%
Impairment of goodwill	\$ -	\$ 15.06	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain on disposal of assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of other long-lived assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Inventory obsolescence charges	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Acquisition related costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Public offering costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Stock based compensation	\$ -	\$ 13.02	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other income, net	\$ -	\$ (3.18)	\$ (7.26)	\$ 0.99	\$ (2.67)	\$ (1.33)	\$ (10.27)	\$ (1.48)	\$ (1.55)	\$ (1.68)	\$ (1.82)	\$ (6.54)
Interest on trade accounts receivable	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted EBITDA	\$ 51.62	\$ 102.11	\$ 25.14	\$ 15.50	\$ 16.82	\$ 16.82	\$ 74.27	\$ 16.05	\$ 21.47	\$ 21.47	\$ 21.47	\$ 80.45
Adjusted EBITDA Margin (%)	26.7%	49.7%	53.1%	35.7%	38.8%	38.8%	41.9%	37.0%	44.0%	44.0%	44.0%	42.4%

SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
Cash Flow Statement
 \$ in Millions

	2023 Actual	2024 Actual	2025 Estimated					2026 Estimated				
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QE Dec-25	Fiscal 2025E	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Net income	\$ 38.56	\$ 46.69	\$ 21.49	\$ 2.44	\$ 12.83	\$ 10.30	\$ 47.07	\$ 9.94	\$ 13.24	\$ 13.31	\$ 13.40	\$ 49.89
Stock-based compensation	\$ -	\$ 13.02	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Depreciation, depletion and amortization	\$ 12.25	\$ 3.80	\$ 0.63	\$ 0.64	\$ 0.75	\$ 0.75	\$ 2.76	\$ 0.75	\$ 0.75	\$ 0.75	\$ 0.75	\$ 2.99
Amortization of debt origination costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Bad debt expense	\$ 0.37	\$ (0.40)	\$ 0.03	\$ 0.26	\$ 0.02	\$ -	\$ 0.31	\$ -	\$ -	\$ -	\$ -	\$ -
Gain/(loss) on disposal of property and equipment	\$ (0.25)	\$ 0.51	\$ (0.01)	\$ 0.00	\$ (0.40)	\$ -	\$ (0.41)	\$ -	\$ -	\$ -	\$ -	\$ -
Gain from sale of equipment damaged or lost	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of goodwill	\$ -	\$ 15.06	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain on sale of business	\$ -	\$ (3.81)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of other long-lived assets	\$ 0.20	\$ 0.53	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Deferred income taxes	\$ 4.11	\$ (14.42)	\$ 7.02	\$ 0.44	\$ 1.65	\$ -	\$ 9.10	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 3.08	\$ 6.49	\$ (7.62)	\$ 1.33	\$ 0.11	\$ -	\$ (6.18)	\$ -	\$ -	\$ -	\$ -	\$ -
Subtotal	\$ 58.32	\$ 67.47	\$ 21.53	\$ 5.11	\$ 14.96	\$ 11.05	\$ 52.64	\$ 10.69	\$ 13.98	\$ 14.06	\$ 14.14	\$ 52.88
Accounts receivable, net - decrease (increase)	\$ (0.60)	\$ 17.74	\$ (0.15)	\$ (0.64)	\$ (0.29)	\$ -	\$ (1.08)	\$ -	\$ -	\$ -	\$ -	\$ -
Receivables from related parties - decrease (increase)	\$ (5.41)	\$ (4.64)	\$ (0.30)	\$ (15.14)	\$ (9.67)	\$ -	\$ (25.11)	\$ -	\$ -	\$ -	\$ -	\$ -
Inventories - decrease (increase)	\$ (1.83)	\$ 1.13	\$ 1.60	\$ (2.32)	\$ 0.98	\$ -	\$ 0.27	\$ -	\$ -	\$ -	\$ -	\$ -
Pre-paid expenses and other assets - decrease (increase)	\$ (0.77)	\$ (2.05)	\$ (3.15)	\$ 2.10	\$ (0.77)	\$ -	\$ (1.82)	\$ -	\$ -	\$ -	\$ -	\$ -
Accounts payable - decrease (increase)	\$ 12.18	\$ (9.59)	\$ 3.24	\$ (4.65)	\$ 3.96	\$ -	\$ 2.55	\$ -	\$ -	\$ -	\$ -	\$ -
Payables to related parties - decrease (increase)	\$ -	\$ (34.08)	\$ (0.11)	\$ 0.11	\$ (10.62)	\$ -	\$ (10.62)	\$ -	\$ -	\$ -	\$ -	\$ -
Accrued expenses and other liabilities - decrease (increase)	\$ (24.59)	\$ (26.63)	\$ (3.10)	\$ (4.51)	\$ (5.53)	\$ -	\$ (13.14)	\$ -	\$ -	\$ -	\$ -	\$ -
Income taxes payable - decrease (increase)	\$ 13.36	\$ 11.23	\$ (17.64)	\$ 11.60	\$ (13.91)	\$ -	\$ (19.94)	\$ -	\$ -	\$ -	\$ -	\$ -
Operating Activities - Net Cash Flow	\$ 50.67	\$ 20.58	\$ 1.93	\$ (8.34)	\$ (20.88)	\$ 11.05	\$ (16.24)	\$ 10.69	\$ 13.98	\$ 14.06	\$ 14.14	\$ 52.88
Purchases of property and equipment	\$ (10.23)	\$ (3.41)	\$ (0.76)	\$ (0.51)	\$ (0.18)	\$ (0.48)	\$ (1.92)	\$ (0.49)	\$ (0.49)	\$ (0.49)	\$ (0.49)	\$ (1.97)
Business divestitures, net of cash transferred	\$ 0.72	\$ (5.07)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Acquisition, net of cash	\$ -	\$ -	\$ -	\$ -	\$ (14.86)	\$ -	\$ (14.86)	\$ -	\$ -	\$ -	\$ -	\$ -
Purchases of property and equipment from related parties	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Contributions to others	\$ (1.70)	\$ 0.41	\$ 0.09	\$ 15.50	\$ 2.28	\$ -	\$ 17.87	\$ -	\$ -	\$ -	\$ -	\$ -
Proceeds from disposal of property and equipment	\$ 8.05	\$ -	\$ 0.32	\$ 1.41	\$ 1.03	\$ -	\$ 2.76	\$ -	\$ -	\$ -	\$ -	\$ -
Purchase of investments	\$ 4.95	\$ (2.03)	\$ (0.64)	\$ (0.02)	\$ (0.43)	\$ -	\$ (1.08)	\$ -	\$ -	\$ -	\$ -	\$ -
Investing Activities - Net Cash Flow	\$ 1.79	\$ (10.10)	\$ (0.98)	\$ 16.38	\$ (12.16)	\$ (0.48)	\$ 2.76	\$ (0.49)	\$ (0.49)	\$ (0.49)	\$ (0.49)	\$ (1.97)
Borrowings on long-term debt	\$ -	\$ 6.60	\$ -	\$ -	\$ 14.85	\$ -	\$ 14.85	\$ -	\$ -	\$ -	\$ -	\$ -
Borrowings on long-term debt - related parties	\$ 12.31	\$ 5.48	\$ 0.02	\$ -	\$ -	\$ -	\$ 0.02	\$ -	\$ -	\$ -	\$ -	\$ -
Repayments of long-term debt	\$ (16.44)	\$ (0.86)	\$ (0.06)	\$ (0.05)	\$ (0.62)	\$ -	\$ (0.72)	\$ -	\$ -	\$ -	\$ -	\$ -
Proceeds from financing transaction	\$ 0.00	\$ 11.74	\$ -	\$ -	\$ (5.00)	\$ -	\$ (5.00)	\$ -	\$ -	\$ -	\$ -	\$ -
Proceeds from sale/leaseback transaction	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Payments on sale/leaseback transaction	\$ -	\$ -	\$ (0.22)	\$ (0.06)	\$ 0.28	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Dividends paid	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Principal payments on financing leases/notes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Debt issuance costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 10.26	\$ -	\$ (0.02)	\$ 7.28	\$ 2.06	\$ -	\$ 9.32	\$ -	\$ -	\$ -	\$ -	\$ -
Financing Activities - Net Cash Flow	\$ 6.14	\$ 22.97	\$ (0.28)	\$ 7.18	\$ 11.57	\$ -	\$ 18.47	\$ -	\$ -	\$ -	\$ -	\$ -
Exchange rate effect	\$ (7.31)	\$ (11.43)	\$ 6.34	\$ 5.47	\$ (3.84)	\$ -	\$ 7.97	\$ -	\$ -	\$ -	\$ -	\$ -
Cash and Equivalents - Change	\$ 51.28	\$ 22.02	\$ 7.01	\$ 20.68	\$ (25.31)	\$ 10.57	\$ 12.96	\$ 10.20	\$ 13.49	\$ 13.57	\$ 13.65	\$ 50.91
Cash Beginning	\$ 51.74	\$ 103.02	\$ 125.04	\$ 132.06	\$ 152.74	\$ 127.43	\$ 125.04	\$ 138.00	\$ 148.20	\$ 161.69	\$ 175.26	\$ 138.00
Cash End	\$ 103.02	\$ 125.04	\$ 132.06	\$ 152.74	\$ 127.43	\$ 138.00	\$ 138.00	\$ 148.20	\$ 161.69	\$ 175.26	\$ 188.91	\$ 188.91

SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
 Balance Sheet
 \$ in Millions

	2023 Actual	2024 Actual	2025 Estimated					2026 Estimated				
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QE Dec-25	Fiscal 2025E	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Cash & equivalents	\$ 103.02	\$ 125.04	\$ 132.06	\$ 152.74	\$ 127.43	\$ 138.00	\$ 138.00	\$ 148.20	\$ 161.69	\$ 175.26	\$ 188.91	\$ 188.91
Short term investments	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Restricted Cash	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Accounts receivable, net	\$ 1.44	\$ 1.41	\$ 1.63	\$ 2.35	\$ 2.61	\$ 2.61	\$ 2.61	\$ 2.67	\$ 2.67	\$ 2.67	\$ 2.67	\$ 2.67
Receivables from related parties, net	\$ 48.31	\$ 45.22	\$ 46.74	\$ 70.49	\$ 79.94	\$ 79.94	\$ 79.94	\$ 80.71	\$ 80.71	\$ 80.71	\$ 80.71	\$ 80.71
Inventories	\$ 3.09	\$ 1.50	\$ 1.70	\$ 1.71	\$ 1.68	\$ 1.68	\$ 1.68	\$ 1.73	\$ 1.73	\$ 1.73	\$ 1.73	\$ 1.73
Pre-paid expenses	\$ 10.05	\$ 11.28	\$ 32.97	\$ 14.05	\$ 14.71	\$ 14.71	\$ 14.71	\$ 15.15	\$ 15.15	\$ 15.15	\$ 15.15	\$ 15.15
Other current assets	\$ -	\$ -	\$ -	\$ -	\$ 0.84	\$ 0.84	\$ 0.84	\$ 0.84	\$ 0.84	\$ 0.84	\$ 0.84	\$ 0.84
Total Current Assets	\$ 165.91	\$ 184.45	\$ 215.10	\$ 241.34	\$ 227.20	\$ 237.77	\$ 237.77	\$ 249.30	\$ 262.80	\$ 276.37	\$ 290.02	\$ 290.02
Property & equipment, net	\$ 13.58	\$ 8.77	\$ 8.52	\$ 8.06	\$ 7.00	\$ 7.00	\$ 7.00	\$ 7.00	\$ 7.00	\$ 7.00	\$ 7.00	\$ 7.00
Operating lease right-of-use assets	\$ 5.92	\$ 5.27	\$ 5.15	\$ 5.15	\$ 4.89	\$ 4.89	\$ 4.89	\$ 4.89	\$ 4.89	\$ 4.89	\$ 4.89	\$ 4.89
Intangible assets, net - customer relationships	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Intangible assets, net	\$ 19.74	\$ 1.59	\$ 1.54	\$ 1.59	\$ 23.30	\$ 23.30	\$ 23.30	\$ 23.30	\$ 23.30	\$ 23.30	\$ 23.30	\$ 23.30
Goodwill	\$ 3.59	\$ 4.61	\$ 4.78	\$ 5.01	\$ 4.93	\$ 4.93	\$ 4.93	\$ 5.42	\$ 5.42	\$ 5.42	\$ 5.42	\$ 5.42
Deferred income tax asset	\$ -	\$ 9.80	\$ -	\$ 2.34	\$ 0.61	\$ 0.61	\$ 0.61	\$ 0.61	\$ 0.61	\$ 0.61	\$ 0.61	\$ 0.61
Other non-current assets	\$ 50.07	\$ 51.59	\$ 49.51	\$ 51.81	\$ 53.44	\$ 53.44	\$ 53.44	\$ 53.44	\$ 53.44	\$ 53.44	\$ 53.44	\$ 53.44
TOTAL ASSETS	\$ 258.81	\$ 266.09	\$ 284.61	\$ 315.30	\$ 321.36	\$ 331.93	\$ 331.93	\$ 343.96	\$ 357.45	\$ 371.02	\$ 384.67	\$ 384.67
Accounts payable	\$ 26.53	\$ 13.88	\$ 17.85	\$ 16.29	\$ 17.26	\$ 17.26	\$ 17.26	\$ 17.69	\$ 17.69	\$ 17.69	\$ 17.69	\$ 17.69
Payables to related parties	\$ 3.37	\$ 0.69	\$ 2.57	\$ 9.33	\$ 4.48	\$ 4.48	\$ 4.48	\$ 4.59	\$ 4.59	\$ 4.59	\$ 4.59	\$ 4.59
Accrued expenses & other current liabilities	\$ 26.67	\$ 11.75	\$ 8.56	\$ 6.74	\$ 7.99	\$ 7.99	\$ 7.99	\$ 8.19	\$ 8.19	\$ 8.19	\$ 8.19	\$ 8.19
Accrued expenses & other current liab/related parties	\$ 23.06	\$ 11.74	\$ 13.50	\$ 10.33	\$ 7.35	\$ 7.35	\$ 7.35	\$ 7.54	\$ 7.54	\$ 7.54	\$ 7.54	\$ 7.54
Current operating lease liability	\$ 3.89	\$ 4.34	\$ 4.29	\$ 3.79	\$ 3.69	\$ 3.69	\$ 3.69	\$ 3.69	\$ 3.69	\$ 3.69	\$ 3.69	\$ 3.69
Current portion of long term debt	\$ 0.16	\$ 0.10	\$ 0.07	\$ 0.07	\$ 3.04	\$ 3.04	\$ 3.04	\$ 3.04	\$ 3.04	\$ 3.04	\$ 3.04	\$ 3.04
Income taxes payable	\$ 8.78	\$ 18.71	\$ 1.62	\$ 14.13	\$ 0.77	\$ 0.77	\$ 0.77	\$ 0.79	\$ 0.79	\$ 0.79	\$ 0.79	\$ 0.79
Total Current Liabilities	\$ 92.45	\$ 61.19	\$ 48.47	\$ 60.68	\$ 44.58	\$ 44.58	\$ 44.58	\$ 45.53	\$ 45.53	\$ 45.53	\$ 45.53	\$ 45.53
Long-term debt (revolver), net of current portion	\$ 1.06	\$ 6.50	\$ 6.80	\$ 7.03	\$ 18.08	\$ 18.08	\$ 18.08	\$ 18.08	\$ 18.08	\$ 18.08	\$ 18.08	\$ 18.08
Long-term debt from related parties	\$ 11.95	\$ 0.01	\$ 0.01	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Deferred income tax liability	\$ 6.01	\$ 0.93	\$ 0.35	\$ 0.35	\$ 7.77	\$ 7.77	\$ 7.77	\$ 7.77	\$ 7.77	\$ 7.77	\$ 7.77	\$ 7.77
Long-term operating lease liability	\$ 2.44	\$ 1.24	\$ 1.51	\$ 1.37	\$ 1.70	\$ 1.70	\$ 1.70	\$ 1.70	\$ 1.70	\$ 1.70	\$ 1.70	\$ 1.70
Asset retirement obligations	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other long-term liabilities	\$ 1.08	\$ 1.19	\$ 1.15	\$ 1.21	\$ 1.17	\$ 1.17	\$ 1.17	\$ 1.17	\$ 1.17	\$ 1.17	\$ 1.17	\$ 1.17
TOTAL LIABILITIES	\$ 115.00	\$ 71.06	\$ 58.28	\$ 70.65	\$ 73.30	\$ 73.30	\$ 73.30	\$ 74.25	\$ 74.25	\$ 74.25	\$ 74.25	\$ 74.25
Common stock	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01
Additional paid-in capital	\$ 36.88	\$ 62.51	\$ 62.51	\$ 72.21	\$ 72.20	\$ 72.20	\$ 72.20	\$ 72.20	\$ 72.20	\$ 72.20	\$ 72.20	\$ 72.20
Retained earnings	\$ 142.85	\$ 189.46	\$ 210.97	\$ 213.41	\$ 226.25	\$ 236.82	\$ 236.82	\$ 247.89	\$ 261.39	\$ 274.96	\$ 288.61	\$ 288.61
Accumulated comprehensive income/(loss)	\$ (37.58)	\$ (54.18)	\$ (44.34)	\$ (35.92)	\$ (42.72)	\$ (42.72)	\$ (42.72)	\$ (42.72)	\$ (42.72)	\$ (42.72)	\$ (42.72)	\$ (42.72)
Non-controlling interest	\$ 1.65	\$ (0.09)	\$ (0.12)	\$ 0.06	\$ 0.07	\$ 0.07	\$ 0.07	\$ 0.07	\$ 0.07	\$ 0.07	\$ 0.07	\$ 0.07
Less: treasury stock	\$ -	\$ (2.70)	\$ (2.70)	\$ (5.12)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)
TOTAL EQUITY	\$ 143.81	\$ 195.02	\$ 226.32	\$ 244.65	\$ 248.06	\$ 258.63	\$ 258.63	\$ 269.70	\$ 283.20	\$ 296.77	\$ 310.42	\$ 310.42
TOTAL LIABILITIES & EQUITY	\$ 258.81	\$ 266.09	\$ 284.61	\$ 315.30	\$ 321.36	\$ 331.94	\$ 331.94	\$ 343.95	\$ 357.45	\$ 371.01	\$ 384.67	\$ 384.67

SBC Medical Group Holdings, Inc.
Nasdaq: SBC
Discounted Cash Flow Model (DCF)
(\$ in millions, except per share)

Estimates:	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	Terminal Value
Revenue	\$ 177.40	\$ 189.68	\$ 213.39	\$ 237.93	\$ 262.91	\$ 287.88	\$ 312.36	\$ 335.78	\$ 357.61	\$ 377.28	
Operating Income	\$ 70.52	\$ 76.75	\$ 85.35	\$ 95.17	\$ 105.16	\$ 115.15	\$ 124.94	\$ 134.31	\$ 143.04	\$ 150.91	
Less: Taxes (benefit)	\$ 33.60	\$ 33.24	\$ 34.14	\$ 38.07	\$ 42.07	\$ 46.06	\$ 49.98	\$ 53.73	\$ 57.22	\$ 60.36	
NOPAT	\$ 36.92	\$ 43.51	\$ 51.21	\$ 57.10	\$ 63.10	\$ 69.09	\$ 74.97	\$ 80.59	\$ 85.83	\$ 90.55	
Add: Depreciation & Amortization	\$ 2.76	\$ 2.99	\$ 2.84	\$ 2.70	\$ 2.89	\$ 3.17	\$ 3.44	\$ 3.69	\$ 3.93	\$ 4.15	
Add: Changes in NWC	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Less: Capital Expenditures	\$ 1.92	\$ 1.97	\$ 2.67	\$ 2.97	\$ 3.29	\$ 3.60	\$ 3.90	\$ 4.20	\$ 4.47	\$ 4.72	
Free Cash Flow	\$ 37.76	\$ 44.53	\$ 51.38	\$ 56.82	\$ 62.70	\$ 68.66	\$ 74.50	\$ 80.08	\$ 85.29	\$ 89.98	\$ 1,145.32
Discount Period - Months	1.00	13.00	25.00	37.00	49.00	61.00	73.00	85.00	97.00	109.00	109.00
Discount Period - Years	0.08	1.08	2.08	3.08	4.08	5.08	6.08	7.08	8.08	9.08	9.08
Discount Factor	0.08	0.89	0.80	0.72	0.65	0.59	0.53	0.47	0.43	0.38	0.38
Present Value of FCF	\$ 3.12	\$ 39.73	\$ 41.27	\$ 41.08	\$ 40.81	\$ 40.22	\$ 39.29	\$ 38.02	\$ 36.44	\$ 34.61	\$ 440.53

Growth Rate Assumptions:

Revenue (1% stepdown/year)	12.5%
Terminal Growth Rate (g):	3.0%
Discount Rate at WACC:	11.1%

Margin Assumptions:

Operating Income	40.0%
D&A as a % of sales (long-term)	1.1%
Taxes	40.0%
Changes in WC	0.0%
Capex as a % of sales	1.3%

Valuation:

Shares Outstanding	102.64
PV of FCF	\$ 354.60
PV of Terminal Value	\$ 440.53
Enterprise Value	\$ 795.12
less: Net Debt (Q4:25E)	(116.88)
less: Minority Interest (Q4:25E)	\$ 0.07
Estimated Total Value	\$ 911.93
Est. Equity Value per Share	\$ 8.88

Price Target Sensitivity Analysis:

Discount Rate		Terminal Growth Rate (g)				
		1.0%	2.0%	3.0%	4.0%	5.0%
10.0%	10.0%	8.91	9.47	10.19	11.16	12.51
	10.5%	8.45	8.93	9.55	10.35	11.44
	11.0%	8.04	8.46	8.98	9.65	10.55
	11.5%	7.67	8.03	8.48	9.05	9.80
	12.0%	7.33	7.65	8.04	8.53	9.16